ライフサイエンスコーパス: rabies vaccine

1 ping potential therapeutics and an avirulent rabies vaccine.

2 guide the development of a single-dose human rabies vaccine.

3 fluenced the prevalence of antibodies to the rabies vaccine.

4 99 to receive RTS,S/AS01 and 101 to receive rabies vaccine.

5 need to develop single-dose and long-lasting rabies vaccines.

6 implications in the development of efficient rabies vaccines.

7 crease our ability to produce more-effective rabies vaccines.

8 which may help in designing more-efficacious rabies vaccines.

9 r (GM-CSF) can enhance the immunogenicity of rabies vaccines.

10 hich will help in designing more efficacious rabies vaccines.

11 ses of RTS,S/AS01E vaccine (223 children) or rabies vaccine (224 controls).

12 ecombinant glycoprotein (rgp) 120 or subunit rabies vaccine administered by the intramuscular route.

13 d in the form of an effective oral wild-life rabies vaccine, although no product for humans has been

14 ly a total of 81 (57.0%) tested positive for rabies vaccine antibodies, possibly, due to the delayed

15 Rabies vaccines are a critical component in the strategy

16 While rabies vaccines are inactivated and thus have an excelle

17 Nevertheless, an experimental rabies vaccine based on the Pittman Moore vaccine strain

18 receive three doses of either RTS,S/AS01 or rabies vaccine (both 0.5 mL per dose by intramuscular in

19 This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a v

20 n naive volunteers during a 3-dose course of rabies vaccine compared with the B-cell response to a bo

21 andidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a pote

22 Currently, safe and efficacious rabies vaccines for humans and animals are produced in s

23 ith the B-cell response to a booster dose of rabies vaccine given to previously immunized volunteers.

24 Rabies vaccines have evolved from the first crude nerve

25 Semple rabies vaccine-induced autoimmune encephalomyelitis (SAE

26 Semple rabies vaccine is derived from brain tissue infected wit

27 prophylaxis using rabies immune globulin and rabies vaccine is effective in preventing rabies followi

28 An efficacious and cost-effective rabies vaccine is needed.

29 recipients and 37 (36.6%, 27.3-46.8) of 101 rabies-vaccine recipients (relative risk 1.1, 95% CI 0.8

30 1 recipients and four (4.0%, 1.1-9.8) of 101 rabies-vaccine recipients died, but no deaths were deeme

31 1 recipients and 12 (11.9%, 6.3-19.8) of 101 rabies-vaccine recipients had at least one serious adver

32 case of Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case of tuberculosis

33 of pneumonia (1% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), five cases of gastroenteriti

34 troenteritis (3% RTS,S/AS01 recipients vs 2% rabies-vaccine recipients), five cases of malnutrition (

35 -vaccine recipients), one case of sepsis (1% rabies-vaccine recipients), one case of Haemophilus infl

36 malnutrition (2% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), one case of sepsis (1% rabie

37 ate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE.

38 In this study, a novel rabies vaccine that expressed murine IL-7 was developed.

39 ss efficient and unsafe nerve-tissue-derived rabies vaccines, the burden of this disease could be sub

40 (PEP) currently comprises administration of rabies vaccine together with rabies immunoglobulin (RIG)

41 us can be targeted to increase the safety of rabies vaccine vectors.

42 e to the delayed uptake of bait in which the rabies vaccine was already inactivated.

43 coma while a native immune response matured; rabies vaccine was not administered.

44 Response to the rabies vaccine was not significantly associated with bir

45 ration of sequential doses of an intradermal rabies vaccine was shown to result in reduced vaccine im

46 In this work, a PIV5-vectored rabies vaccine was tested in mice.

47 vaccine for Salmonella typhi and 2 doses of rabies vaccine were given to each subject.

48 rategy to develop a single-dose postexposure rabies vaccine where the generation of early protective